Use Of High-Dose Allopurinol To Reach Serum Uric Acid Targets In Patients With Gout Across Multiple Countries

被引：0
|
作者：
Singh, Jasvinder A. [1 ]
Storgard, Chris [2 ]
Baumgartner, Scott [2 ]
Morlock, Robert [2 ]
机构：
[1] Univ Alabama, Tuscaloosa, AL USA
[2] Ardea Biosci, San Diego, CA USA
来源：
ARTHRITIS AND RHEUMATISM | 2013年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1186
引用
收藏
页码：S502 / S502
页数：1
相关论文
共 50 条
  • [21] DECREASED ORAL TOXICITY WITH THE LOCAL USE OF ALLOPURINOL IN PATIENTS WHO RECEIVED HIGH-DOSE 5-FLUOROURACIL
    TSAVARIS, NB
    KOMITSOPOULOU, P
    TZANNOU, I
    LOUCATOU, P
    TSAROUCHANOUTSOU, A
    KILAFIS, G
    KOSMIDIS, P
    SELECTIVE CANCER THERAPEUTICS, 1991, 7 (03): : 113 - 117
  • [22] Allopurinol as a Preventive Contrivance after Acute Ischemic Stroke in Patients with a High Level of Serum Uric Acid: A Randomized, Controlled Trial
    Taheraghdam, Ali Akbar
    Sharifipour, Ehsan
    Pashapour, Ali
    Namdar, Shahryar
    Hatami, Abolfazl
    Houshmandzad, Samaneh
    Sadeghihokmabadi, Elyar
    Tazik, Mokhtar
    Rikhtegar, Reza
    Mahmoodpoor, Ata
    MEDICAL PRINCIPLES AND PRACTICE, 2014, 23 (02) : 134 - 139
  • [23] Allopurinol as a preventive contrivance after acute ischemic stroke in patients with high level of serum uric acid: A randomized, controlled trial
    Sharifipour, E.
    Taheraghdam, A.
    Houshmandzad, S.
    INTERNATIONAL JOURNAL OF STROKE, 2014, 9 : 37 - 37
  • [24] Letter by Kielstein et al regarding article, "High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid"
    Kielstein, Jan T.
    Woywodt, Alexander
    Salpeter, Shelley R.
    CIRCULATION, 2007, 115 (18) : E450 - E450
  • [25] SERUM miRNA PROFILES ARE ALTERED IN PRIMARY SCLEROSING CHOLANGITIS PATIENTS TREATED WITH HIGH-DOSE URSODEOXYCHOLIC ACID
    Hochberg, Jessica
    Handa, Priya
    Maliken, Bryan D.
    Kim, Taek-Kyun
    Wang, Kai
    Gochanour, Eric
    Li, Yu
    Rose, J. Bart
    Nelson, James E.
    Lindor, Keith D.
    LaRusso, Nicholas F.
    Kowdley, Kris V.
    HEPATOLOGY, 2022, 76 : S1520 - S1521
  • [26] Serum miRNA profiles are altered in patients with primary sclerosing cholangitis receiving high-dose ursodeoxycholic acid
    Hochberg, Jessica T.
    Sohal, Aalam
    Handa, Priya
    Maliken, Bryan D.
    Kim, Take-Kyun
    Wang, Kai
    Gochanour, Eric
    Li, Yu
    Rose, J. Bart
    Nelson, James E.
    Lindor, Keith D.
    LaRusso, Nicholas F.
    Kowdley, Kris V.
    JHEP REPORTS, 2023, 5 (06)
  • [27] Serum Bile Acid Profiles After High-Dose Ursodeoxycholic Acid Treatment in Patients With Primary Sclerosing Cholangitis: Clinical Implications
    Sinakos, Emmanouil
    Marschall, Hanns-Ulrich
    Kowdley, Kris V.
    Befeler, Alex
    Keach, Jill C.
    Lindor, Keith D.
    GASTROENTEROLOGY, 2010, 138 (05) : S786 - S786
  • [28] Serum MicroRNA: Novel Prognostic Biomarkers in Primary Sclerosing Cholangitis Patients Treated With High-Dose Ursodeoxycholic Acid
    Li, Yu
    Shah, Nihar
    Nelson, James E.
    Lindor, Keith D.
    Talwalkar, Jayant
    Kowdley, Kris V.
    GASTROENTEROLOGY, 2013, 144 (05) : S254 - S254
  • [29] DOES HIGH SERUM URIC ACID INCREASE THE RISK OF RENAL DISEASE IN PATIENTS WITH GOUT? RESULTS FROM A RETROSPECTIVE ANALYSIS OF ELECTRONIC HEALTH RECORD DATA
    Essex, M. N.
    Hopps, M.
    Udall, M.
    Fu, C.
    Bienen, E. J.
    Mardekian, J.
    Makinson, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 541 - 542
  • [30] PARATHYROID-HORMONE, CAMP, ELECTROLYTES AND URIC-ACID AFTER HIGH-DOSE CACL2 IN PATIENTS WITH IDIOPATHIC STONE FORMATION
    DUNZENDORFER, U
    SCHMIDTGAYK, H
    ENDOKRINOLOGIE, 1981, 77 (03): : 353 - 359
12345